Answers are grounded in this paper and cite their sources.
Diffuse Large B-cell Lymphoma (DLBCL) is a highly heterogeneous cancer of B cells.Apart from cell-of-origin, genetic variations have been observed to contribute towards heterogeneity leading to different pathogenic mechanisms and overall survival outcomes.Various classification schemes have been proposed that may aid in risk stratification and developing new therapeutics for those who fail frontline therapy.This mini review highlights the significance of genetic variations as biomarkers for DLBCL and ease in extending it to clinical setting.
No takes yet. Share an insight, caveat, or question.
Nita Parekh (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: